Search Results - "BRUIX, J"

Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment by Sapisochin, G., Facciuto, M., Rubbia‐Brandt, L., Marti, J., Mehta, N., Yao, F.Y., Vibert, E., Cherqui, D., Grant, D.R., Hernandez‐Alejandro, R., Dale, C.H., Cucchetti, A., Pinna, A., Hwang, S., Lee, S.G., Agopian, V.G., Busuttil, R.W., Rizvi, S., Heimbach, J.K., Montenovo, M., Reyes, J., Cesaretti, M., Soubrane, O., Reichman, T., Seal, J., Kim, P.T.W., Klintmalm, G., Sposito, C., Mazzaferro, V., Dutkowski, P., Clavien, P.A., Toso, C., Majno, P., Kneteman, N., Saunders, C., Bruix, J.

“…The presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is a contraindication for liver transplantation in most centers worldwide…”
Get full text

THU-12 Combination of liver directed therapies with systemic therapies by Bruix, J

Get full text

Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) by Köchert, K., Meinhardt, G., Bruix, J., Teufel, M.

Get full text

Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma by Toso, C., Mazzaferro, V., Bruix, J., Freeman, R., Mentha, G., Majno, P.

“…In some countries where the Model for End‐Stage Liver Disease (MELD) score is used for graft allocation, selected patients with hepatocellular carcinoma (HCC)…”
Get full text

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference by Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., Colombo, M., Delarocque-Astagneau, E., Dusheiko, G., Esmat, G., Esteban, R., Goldberg, D., Gore, C., Lok, A. S. F., Manns, M., Marcellin, P., Papatheodoridis, G., Peterle, A., Prati, D., Piorkowsky, N., Rizzetto, M., Roudot-Thoraval, F., Soriano, V., Thomas, H. C., Thursz, M., Valla, D., van Damme, P., Veldhuijzen, I. K., Wedemeyer, H., Wiessing, L., Zanetti, A. R., Janssen, H. L. A.

“…Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600 000 and 350 000 deaths each year. Viral hepatitis is the…”
Get full text

Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation: A Spanish Matched Cohort Multicenter Study by Sapisochin, G, de Lope, C Rodríguez, Gastaca, M, de Urbina, J Ortiz, López-Andujar, R, Palacios, F, Ramos, E, Fabregat, J, Castroagudín, J F, Varo, E, Pons, J A, Parrilla, P, González-Diéguez, M L, Rodriguez, M, Otero, A, Vazquez, M A, Zozaya, G, Herrero, J I, Antolin, G Sanchez, Perez, B, Ciria, R, Rufian, S, Fundora, Y, Ferron, J A, Guiberteau, A, Blanco, G, Varona, M A, Barrera, M A, Suarez, M A, Santoyo, J, Bruix, J, Charco, R

“…OBJECTIVE:To evaluate the outcome of patients with hepatocellular-cholangiocarcinoma (HCC-CC) or intrahepatic cholangiocarcinoma (I-CC) on pathological…”
Get full text

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis by Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J

“…Background: The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral,…”
Get full text

New aspects of diagnosis and therapy of hepatocellular carcinoma by Bruix, J, Hessheimer, A J, Forner, A, Boix, L, Vilana, R, Llovet, J M

“…Hepatocellular carcinoma is one of the major cancer killers. It affects patients with chronic liver disease who have established cirrhosis, and currently is…”
Get full text

Restoring MIR122 in Human Stem-Like Hepatocarcinoma Cells, Prompts Tumor Dormancy through Smad-Independent TGF-B Pathway by Boix, L, Lopez-Oliva, J.M, Rhodes, A.C, Bruix, J

Get full text

Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib by Fonseca, L.G.D., Díaz, A., Sapena, V., Díaz-González, Á, Boix, L., Sanduzzi-Zamparelli, M., Fuster, C., Llarch, N., Iserte, G., Torres, F., Bruix, J., Reig, M.

Get full text

Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure by Bruix, J, Castells, A, Bosch, J, Feu, F, Fuster, J, Garcia-Pagan, JC, Visa, J, Bru, C, Rodes, J

“…BACKGROUND & AIMS: Although resection of hepatocellular carcinoma complicating cirrhosis is restricted to patients with preserved liver function, postoperative…”
Get full text

Cerium oxide nanoparticles display anti-tumoral activity and improve survival in experimental hepatocellular carcinoma by Fernandez-Varo, G, Oró, D, Yudina, T, Carvajal, S, Marfà, S, Boix, L, Perramón, M, Oller, L, Casals, G, Morales-Ruiz, M, Casado, P, Cutillas, P.R, Bruix, J, Puntes, V, Jiménez, W

Get full text

Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth by Reig, M, Mariño, Z, Perelló, C, Iñarrairaegui, M, Lens, S, Díaz, A, Vilana, R, Darnell, A, Varela, M, Sangro, B, Calleja, J.L, Forns, X, Bruix, J

Get full text

Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence by Diaz-Gonzalez, A, Darnell, A, Rimola, J, Belmonte, E, Loreto, B, Neus, L, Forner, A, Iserte, G, Ayuso, C, Feu, F, Bruix, J, Reig, M

Get full text

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation by Llovet, J M, Mas, X, Aponte, J J, Fuster, J, Navasa, M, Christensen, E, Rodés, J, Bruix, J

“…Background: Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor…”
Get full text

P0379 : Cancer related symptoms (performance status 0 vs 1) determine prognosis of hepatocellular carcinoma patients treated with sorafenib. Analysis of a prospective data collection in 207 patients by Varela, M, Reig, M, Álvarez Navascués, C, Forner, A, Cadahía, V, Díaz, Á, González-Diéguez, M.L, Llarch, N, Rodríguez, M, Bruix, J

Get full text

P0390 : Baseline bilirubin and not Child-Pugh a or B7 predicts survival of BCLC B patients treated with sorafenib. The clinical approach to the stratification debate by Gazzola, A, Di Donato, R, Reig, M, Llarch, N, Forner, A, Darnell, A, Rimola, J, Ayuso, C, Bruix, J

Get full text

The Accuracy of the Baseline Peripheral Lymphocyte Value in Predicting Overall Survival in Hepatocellular Carcinoma Patients Treated with Sorafenib Reinforces the Impact of the Immune Response on Tumor Progression by Reig, M, Ribeiro, A, Gazzola, A, Díaz, Á, LLarch, N, Iserte, G, Forner, A, Boix, L, Lopez-Oliva, J.M, Darnell, A, Rimola, J, Ayuso, C, Bruix, J

Get full text

Optimization of Survival Prediction in Patients under Sorafenib Treatment: Usefulness of Carbonic Anhydrase IX Baseline and Baseline and Evolutive Angiopoyetin 2 by Reig, M, Loreto, B, Torres, F, Lopez-Oliva, J.M, Rimola, J, Darnell, A, Forner, A, Díaz, Á, Ribeiro, A, LLarch, N, Ayuso, C, Bruix, J

Get full text

Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment by Bruix, J, Merle, P, Granito, A, Huang, Y.-H, Bodoky, G, Pracht, M, Yokosuka, Rosmorduc, O, Breder, V, Gerolami, R, Masi, G, Ross, P.J, Qin, S, Song, T, Bronowicki, J.-P, Ollivier-Hourmand, I, Kudo, M, Baumhauer, A, LeBerre, M.-A, Meinhardt, G, Han, G

Get full text